以TRDMT1为媒介的RNA C-5甲基化作为抗癌疗法的新目标
Anna Lewinska1, Jagoda Adamczyk-Grochala1, Maciej Wnuk1
1Institute of Biotechnology, College of Natural Sciences, University of Rzeszow, Pigonia 1, 35-310 Rzeszow, Poland.
Biochimica et biophysica acta. Reviews on cancer
|August 25, 2023
概括
在癌症中,RNA的修改会发生变化. 酶TRDMT1 (DNMT2) 甲基化RNA,影响癌症的进展和稳定性. 抑制TRDMT1可能会提高癌症治疗的有效性.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- RNA修饰在癌症发育中至关重要,影响癌症的增殖,迁移,入侵,亡抵抗和代谢重编程.
- DNMT2/TRDMT1,一个5-甲基细胞氨酸甲基转移酶,甲基化tRNA和mRNA,影响tRNA稳定性,蛋白质合成,DNA损伤反应和DNA稳定性.
- 在各种癌症类型中观察到高TRDMT1水平和突变,将其与癌症进展联系起来.
研究的目的:
- 审查TRDMT1在正常和癌细胞中的生理和病理生理作用.
- 展示和评估潜在的TRDMT1基质,抑制剂和调节机制.
- 讨论TRDMT1作为抗癌疗法的潜在目标.
主要方法:
- 关于TRDMT的现有数据的文献综述1.
- 分析TRDMT1在不同生物系统中的作用,重点是人类细胞.
- 对TRDMT1的基质,抑制剂和调节机制的评估.
主要成果:
- TRDMT1在正常细胞功能和癌症进展中起着重要的作用.
- TRDMT1基因淘汰使癌细胞对放射治疗和化疗产生敏感性.
- 在关键癌症特征中TRDMT1的参与表明其治疗潜力.
结论:
- TRDMT1涉及癌细胞生物学和进展的各个方面.
- 向TRDMT1为新型抗癌疗法提供了一个有前途的战略.
- 对TRDMT1的机制和调节进行进一步的研究是治疗开发的必要条件.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Phase II Reactions: Methylation Reactions
229
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
229
Transfer RNA Synthesis
12.0K
One of the unique features of tRNA is the presence of modified bases. In some tRNAs, modified bases account for nearly 20% of the total bases in the molecule. Altogether, these unusual bases protect the tRNA from enzymatic degradation by RNases.
Each of these chemical modifications is carried by a specific enzyme, post-transcription. All of these enzymes have unique base and site-specificity. Methylation, the most common chemical modification, is carried by at least nine different enzymes, with...
Each of these chemical modifications is carried by a specific enzyme, post-transcription. All of these enzymes have unique base and site-specificity. Methylation, the most common chemical modification, is carried by at least nine different enzymes, with...
12.0K
Electron Transport Chain: Complex I and II
14.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.5K


